Jump to content

Midaflur

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Boghog (talk | contribs) at 20:28, 27 February 2020 (consistent citation formatting). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Midaflur
Clinical data
ATC code
  • None
Identifiers
  • 2,2,5,5-Tetrakis(trifluoromethyl)-2,5-dihydro-1H-imidazol-4-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC7H3F12N3
Molar mass357.103 g·mol−1
3D model (JSmol)
  • C1(=NC(NC1(C(F)(F)F)C(F)(F)F)(C(F)(F)F)C(F)(F)F)N
  • InChI=1S/C7H3F12N3/c8-4(9,10)2(5(11,12)13)1(20)21-3(22-2,6(14,15)16)7(17,18)19/h22H,(H2,20,21)
  • Key:KYWMWUUMCDZISK-UHFFFAOYSA-N

Midaflur (INN; EXP 338) is an extremely stable 3-imidazoline derivative with central skeletal muscle relaxant and sedative properties in humans[1] and other species of mammals, exhibiting consistently high oral bioavailability and a long duration of action. While its pharmacodynamics remain poorly understood, midaflur resembles meprobamate and pentobarbital in terms of observed effects while being considerably more potent.[2]

See also

References

  1. ^ Levine IM, Jossmann PB, Friend DG, DeAngelis V (1967). "Effect of 5-imino-2,2,4,4-tetrakis (trifluoromethyl) imidazolidine (EXP 338) on spasticity: A quantitative evaluation". Clinical Pharmacology and Therapeutics. 9 (4): 448–55. doi:10.1002/cpt196894448. PMID 4871898.
  2. ^ Clark R, Lynes TE, Price WA, Smith DH, Woodward JK, Marvel JP, Vernier VG (April 1971). "The pharmacology and toxicology of midaflur". Toxicology and Applied Pharmacology. 18 (4): 917–43. doi:10.1016/0041-008x(71)90239-0. PMID 5570243.